Moexipril Hydrochloride
CI-925 · Perdix · SPM-925 · Univasc · RS-10085 · Fempress · RS-10085-197 · Moexipril HCl - Bio-X ?
Identifikatoren & physikalische Daten
| CAS No. | 82586-52-5 |
|---|---|
| Summenformel | C27H35ClN2O7 |
| Durchschnittliche Molmasse | 535 g/mol |
| Monoisotopische Masse | 534,2132792 g/mol |
| SMILES | CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2cc(OC)c(OC)cc2C[C@H]1C(=O)O.Cl |
| InChIKey | JXRAXHBVZQZSIC-JKVLGAQCSA-N |
| PubChem CID | 54889 |
| ChEMBL | CHEMBL1200534 |
| ChEBI | CHEBI:6961 |
| EC No. | 617-363-1 |
| DTXSID | DTXSID7044267 |
Chemische & physikalische Eigenschaften
| Polarare Oberfläche (TPSA) | 114 |
|---|---|
| H-Brücken-Donoren | 3 |
| H-Brücken-Akzeptoren | 8 |
| Frei drehbare Bindungen | 12 |
| Schwere Atome | 37 |
| Formalladung | 0 |
| Komplexität | 742 |
| Schmelzpunkt | 141-1610C |
| Lagerbedingungen | 2-8°C |
| Löslichkeit | H2O: soluble32mg/mLH2O: 32mg/mL |
| Aggregatzustand | powder |
| Farbe | White to off-white |
| InChIKey | JXRAXHBVZQZSIC-JKVLGAQCSA-N |
| SMILES | Cl.CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N2Cc3cc(OC)c(OC)cc3C[C@H]2C(O)=O |
Sicherheit & Vorschriften
| GHS-Einstufung | WarningH400 (95.1%): Very toxic to aquatic life [Warning Hazardous to the aquatic environment, acute hazard]P273, P391, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 41 reports by companies from 2 notifications to the ECHA C&L Inventory.Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. For more detailed information, please visit ECHA C&L website. |
|---|---|
| Hazard Classes and Categories | Aquatic Acute 1 (95.1%) |
| Drug Induced Liver Injury | Drug Induced Liver Injury Rank (DILIrank 2.0)Moexipril hydrochlorideAmbiguous-DILI-concern3Adverse reactionsDOI:10.1016/j.drudis.2016.02.015 |
| Effects During Pregnancy and Lactation | ◉ Summary of Use during LactationBecause no information is available on the use of moexipril during breastfeeding, an alternate drug may be preferred, especially while nursing a newborn or preterm infant.◉ Effects in Breastfed InfantsRelevant published information was not found as of the revision date.◉ Effects on Lactation and Breastmilk |
| Wassergefährdungsklasse (WGK) | 3 |
| UN-Transportnummer | UN 3077 9/PG 3 |
| Zollcode | 2933492250 |
| RTECS-Nr. | NW7174500 |
| R-Sätze (R) | 50 |
| Gefahrensymbole | N |
| Sicherheitshinweise (S) | 60 |
| Lagerklasse | 11 - Combustible Solids |
Anwendungen & Verwendung
Beschreibung
Moexipril hydrochloride is a novel ACE inhibitor first marketed in the U.S.A. for the treatment of hypertension as a monotherapy and as a second-line therapy in combination with diuretics or calcium antagonists. Like other ACE inhibitors, moexipril is a prodrug that is converted in the liver to its diacid moexiprilat which is the active agent. Moexipril displays a higher in vitro inhibitory potency to ACE than enalapril although its effectiveness in reduction of blood pressure in hypertensive patients is similar to that seen with enalapril. It is orally active with a rapid onset and prolonged duration of action. Excellent tolerability has been reported. Moexipril is distinguished by its lower cost than other marketed ACE inhibitors.
Verwenden
Angiotensin converting enzyme (ACE) inhibitor; dimethoxy analog of quinapril